You just read:

HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

News provided by

HLS Therapeutics Inc.

Mar 19, 2019, 06:32 ET